Hikma has the appetite to make more deals, according to CEO Siggi Olafsson, following a year that has seen it snap up major injectables assets and secure partnerships on US biosimilars.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?